SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group is trending due to a multi-billion dollar AI infrastructure agreement with Microsoft, sparking excitement and bullish sentiment among investors. The community is actively discussing the potential for significant revenue growth and increased valuation, drawing comparisons to other high-performing AI stocks. This deal validates Nebius as a key player in AI capacity, potentially leading to more partnerships and further expansion.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) is trending due to a significant surge, reportedly linked to news of a private placement and strategic investment related to a crypto initiative. The community is actively discussing the stock's massive intraday gains, potential short squeeze dynamics, and comparisons to other high-flying tickers. Some traders express skepticism, pointing to the company's fundamentals and potential dilution, while others remain bullish, anticipating further upside.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to its active community and ongoing development, including upcoming staking app launch and planned token burns. Community members express excitement about the project's momentum, with some suggesting meetups upon reaching certain market cap milestones. The coin's growing number of watchers and exchange listing contribute to the positive sentiment.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to anticipation surrounding an upcoming merger vote, with the community buzzing about the potential for a significant short squeeze and comparing it to other high-momentum plays. Bullish sentiment is fueled by the company's move to become a Bitcoin treasury asset manager and potential access to substantial funding, while others are wary of potential dilution post-merger.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions about its solid-state battery technology and recent demonstrations, including its use in a Ducati motorcycle. Community talking points revolve around the long-term potential, partnership with Volkswagen, and speculation regarding additional OEM partners. Increased short interest is adding to the volatility.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses its future growth drivers beyond car sales, particularly its energy business and upcoming 'Las Megas' event showcasing Megapacks. Concerns are also emerging around declining market share and the impact of expiring EV tax credits, sparking debate about Tesla's valuation and long-term prospects. Sentiment is mixed, with bulls citing potential for AI and robotics while bears point to increasing competition and dependence on subsidies.

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Forward Industries ($FORD) is trending as traders draw comparisons to similar low-float plays like $OCTO, focusing on its smaller float and recent news. The community is discussing the company's Solana treasury strategy, viewing it as a potentially significant catalyst. Some traders are noting price volatility and the stock's inability to hold gains despite positive news.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

SNTG is trending as traders discuss its potential for a significant run, drawing comparisons to recent surges in similar stocks like OCTO. Community members highlight SNTG's low float and potential for a short squeeze, fueling speculative interest. Some traders are also pointing to a potential for increased borrow fees, which could add pressure on shorts.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin ($WLD.X) is trending amidst discussions about its potential, Sam Altman's involvement, and the recent expansion into new regions. Community members are actively debating its use case, particularly around digital identity and AI, while some express concerns about privacy and the project's long-term value. News of key personnel joining the project and treasury initiatives are also driving interest.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

XVM.X is trending as a relatively new crypto, with users actively discussing its potential for high returns and its possible integration with real-world assets; the community is also weighing in on where to purchase it and some are concerned about whether it is a legitimate project or a 'rug pull'.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day

Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.

FDA Approves Updated COVID-19 Vaccines but With Restrictions

FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies IQVIA and Flagship Pioneering Announce Strategic Collaboration to...

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said on Wednesday that the U.S. Food and Drug Administration has approved the application of its LP.8.1-adapted monovalent COVID-19 vaccine for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval">said</a> that the approval is based on a body of evidence supporting the safety and efficacy of the vaccine, including clinical trial data supporting approval for children 5 through 11 years of age.On Stocktwits, retail sentiment around PFE trended within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:622/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_09_36_PM_png_c697ca4665.webp" alt="PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="622" height="60"><figcaption>PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed within ‘bullish’ territory, accompanied by ‘high’ levels of retail chatter.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_10_26_PM_png_722e599af9.webp" alt="Screenshot 2025-08-27 at 2.10.26 PM.png"><figcaption>BNTX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance, the companies said. The companies added that the vaccine will begin shipping immediately and be available in pharmacies, hospitals, and clinics across the U.S. in the coming days.Earlier in the day, U.S. Health Secretary Robert F. Kennedy Jr. <a href="https://stocktwits.com/news-articles/markets/equity/robert-kennedy-jr-announces-end-of-fda-covid-mandates/chsUJ4VRdla">stated</a> in a post on X that the FDA has now granted full marketing authorization for certain COVID-19 vaccines targeting higher-risk groups. Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above, all of whom are at higher risk, he said.“The American people demanded science, safety, and common sense,” Kennedy said.Moderna <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&amp;symbol=MRNA">confirmed</a> the news and said that the FDA has approved its 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated vaccines are expected to be available in the coming days, it said.While Spikevax is now approved in adults over 65 and in people aged 6 months through 64 years at high risk, mNEXSPIKE is approved for individuals 12 through 64 years of age at high risk and all adults over 65, the company said.While PFE stock is down by 6% this year, BNTX stock is down by 9%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uk-regulator-approves-biogen-drug-for-treating-postnatal-depression/chsUel3Rdl9">UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population

The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Equity

The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.


U.S. Health Secretary Robert F. Kennedy Jr. stated on Wednesday that the Food and Drug Administration (FDA) has now granted full marketing authorization for certain&nbsp;Covid&nbsp;vaccines targeting higher-risk groups.&nbsp;The health secretary said that the decision marks a transition away from pandemic-era emergency powers. “The American people demanded science, safety, and common sense. This framework delivers all three,” the secretary said, adding thanks to FDA official Dr. Marty Makary for his role in the process.Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above. In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/SecKennedy/status/1960742897201872969">post</a> on X, Kennedy stated that these will be available to patients who choose vaccination, in consultation with their doctors.&nbsp;<figure class="image"><img style="aspect-ratio:1080/1907;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_22_13_10_04_0b2fce7a16bf2b728d6ffa28c8d60efb_1_jpg_d5715c25ca.webp" alt="Screenshot_2025-08-27-22-13-10-04_0b2fce7a16bf2b728d6ffa28c8d60efb (1).jpg" width="1080" height="1907"><figcaption>Source: @SecKennedy/X</figcaption></figure>The news comes on the heels of a Daily Beast&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thedailybeast.com/donald-trump-and-robert-f-kennedy-junior-to-ban-covid-19-vaccine-within-months/">report</a> which stated that "a decision to remove the (COVID-19) vaccine from the U.S. market pending further research will come ‘within months,’" citing British cardiologist Dr. Aseem Malhotra.&nbsp;<a href="http://stocktwits.com/symbol/MRNA">Modern’s stock</a> edged 0.5% higher in afternoon trade with retail sentiment around the company moving higher within ‘extremely bullish’ territory over the past day.&nbsp;<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> moved 0.4% higher, but retail sentiment continued to trend in the ‘neutral’ zone.&nbsp;<a href="http://stocktwits.com/symbol/NVAX">Novavax’s stock</a> was among the top trending stocks on the platform, but its price fell 0.5% and retail sentiment dipped to ‘neutral’ from the ‘bullish’ zone. The stock has fallen by more than 8% over the past week following the company's&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-suffers-sharpest-drop-in-months-after-225-m-debt-deal-retail-still-leans-bullish/chsmrNiRd0d">announcement</a> of its new debt refinancing plan.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warner-bros-names-brad-singer-cfo-ahead-of-planned-spinoff/chsUE1pRdlI">Warner Bros. Names Brad Singer CFO Ahead Of Planned Spinoff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

Robert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk Groups

Moderna’s Covid vaccine has been authorized for individuals six months and older, Pfizer's for ages five and up, and Novavax's for ages 12 and above. 

Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older.The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season this fall. The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5951824473215334&amp;symbol=MRNA">added</a> that the pre-filled syringe doses of the vaccine for the market will be made domestically. While the drug substance will be produced at the company’s facility in Laval, Quebec, fill-finish operations will be completed by Novocol Pharma in Cambridge, Ontario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">Moderna</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 5% higher on Friday morning at the time of writing.Health Canada authorized the vaccine based on clinical, non-clinical, and real-world data supporting the vaccine’s safety and efficacy, Moderna said. The updated vaccine targets the SARS-CoV-2 LP.8.1 variant.While those Canadians covered by public programs will receive the vaccine free of charge, the company is also working with private insurers and payers to streamline access and reimbursement within the private sector, it said. The updated COVID-19 vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries. Applications are also under review in other markets.In the second quarter, Moderna reported $114 million in Spikevax sales, including $88 million of U.S. sales and $26 million of international sales. Spikevax sales accounted for 80% of the company’s total revenue in the three months through the end of June.MRNA stock is down by 34% this year and by about 66% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ulta-beauty-gets-upgraded-to-overweight-by-barclays/chsZPwFRd0U">Ulta Beauty Gets Upgraded To ‘Overweight’ By Barclays, But Retail Sentiment Cools Ahead Of Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Gets Clearance To Deliver Updated Spikevax COVID-19 Vaccine In Canada

The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season.

Can Keytruda Sustain Merck's Growth Through the Rest of 2025?

MRK banks on Keytruda's soaring sales and new oncology strategies to fuel 2025 growth, even as competition and patent loss loom.

The U.S. Food and Drug Administration (FDA) is reportedly considering revoking the authorization granted to Pfizer Inc. (PFE) to sell its COVID-19 vaccine to children under five.According to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-12/fda-weighs-pulling-pfizer-s-covid-vaccine-for-kids-under-age-5?sref&amp;">report</a>, the company said that the agency informed it that it might not renew its pandemic-era authorization for younger children. Pfizer, however, has requested that the approval stay in place through the coming fall season, the report added.Pfizer is currently in discussions with the FDA on potential paths forward, the firm said in a statement to Bloomberg. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume slipped from ‘extremely high’ to ‘high’ levels. However, retail chatter around Pfizer has soared 467% in the past 30 days.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_12_at_10_06_34_AM_png_8fa863d99a.webp" alt="PFE's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Aug. 12, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>PFE's Sentiment Meter and Message Volume as of 10:06 a.m. ET on Aug. 12, 2025 | Source: Stocktwits</figcaption></figure>If the FDA does not renew authorization for younger children, kids with no health concerns will have no available COVID-19 shots, the report noted. While Moderna’s (MRNA) COVID-19 vaccine is approved in children, it is only approved for children under 12 at increased risk of the disease due to underlying conditions.A Stocktwits user opined that Pfizer stock is undervalued, given all its assets and pipeline.<stembedurl>https://stocktwits.com/myman1956/message/624732762</stembedurl>Another highlighted Pfizer’s data from a late-stage trial earlier in the day, and noted that it might serve as a potential catalyst.<stembedurl>https://stocktwits.com/trading_momentum/message/624749308</stembedurl>Earlier on Tuesday, Pfizer <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/padcevtm-plus-keytrudatm-significantly-improves-survival">announced</a> positive results from a late-stage trial evaluating Astellas Pharma’s Padcev in combination with Merck’s cancer drug Keytruda in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin-based chemotherapy.The trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival and overall survival with the use of Padcev and Keytruda before and after surgery versus surgery alone. PFE stock is down by 7% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-robotaxi-updates-guggenheim-highlights-mixed-signals-from-market/chrxPu3Rd76">Tesla Robotaxi Updates: Guggenheim Highlights ‘Mixed Signals’ From Market, But Retail’s Turned Exuberant For Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5: Retail Says Stock Is Undervalued 

According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 

Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5

According to a Bloomberg report, Pfizer has requested that the approval stay in place through the coming fall season. 


Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Shares of Moderna (MRNA), Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt future mRNA vaccine development under the Biomedical Advanced Research and Development Authority (BARDA).&nbsp;Meanwhile, retail sentiment soured on AstraZeneca (AZN) after its vaccine partnership was identified as part of the federal wind-down.The U.S. Department of Health and Human Services (HHS) said that it will terminate or restructure 22 mRNA vaccine-related projects under BARDA, affecting nearly $500 million in funding.&nbsp;The decision follows a review of pandemic-era investments in mRNA technologies and represents a pivot in vaccine development strategy.“We reviewed the science, listened to the experts, and acted,” said HHS Secretary Robert F. Kennedy, Jr.HHS stated that its decision to terminate 22 mRNA vaccine development projects under BARDA was&nbsp;based on scientific data indicating the limited effectiveness of such vaccines in preventing upper respiratory infections, such as COVID-19 and influenza.&nbsp;The agency plans to redirect funding toward alternative vaccine platforms that offer broader protection and remain effective against evolving viruses.The canceled programs include BARDA’s award to Moderna and the University of Texas Medical Branch for an mRNA-based H5N1 avian flu vaccine.&nbsp;Contracts with Emory University and Tiba Biotech are also being terminated.&nbsp;Existing agreements with Luminary Labs, ModeX, and Seqirus, Sanofi’s vaccine subsidiary, are being revised to exclude mRNA components.Several pre-award solicitations have been rejected or canceled, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others under BARDA’s Rapid Response Partnership Vehicle and VITAL Hub.&nbsp;HHS is also restructuring collaborations with the Department of Defense’s Joint Program Executive Office (JPEO), impacting nucleic acid-based vaccine efforts by AAHI, AstraZeneca, and HDT Bio.While some late-stage contracts, such as those with Arcturus and Amplitude, will be allowed to conclude, HHS said that no new mRNA projects will be initiated under BARDA.&nbsp;Additionally, the department has directed the Global Health Investment Corporation, which manages BARDA Ventures, to stop all equity investments in mRNA technologies.&nbsp;Other uses of mRNA technology within HHS are not impacted by the announcement.“Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That’s why we’re moving beyond the limitations of mRNA and investing in better solutions,” said Kennedy.On Stocktwits, retail sentiment was&nbsp;<a href="https://stocktwits.com/symbol/MRNA">‘bullish’ for MRNA</a> and&nbsp;<a href="https://stocktwits.com/symbol/SNY">SNY</a>, while&nbsp;<a href="https://stocktwits.com/symbol/PFE">PFE saw ‘extremely bullish’ sentiment</a> with ‘extremely high’ message volume. In contrast,&nbsp;<a href="https://stocktwits.com/symbol/AZN">sentiment turned ‘bearish’ for AZN</a>, with message volume remaining ‘normal’.So far this year, MRNA is down 34.6%, PFE is down 7%, SNY is down 0.7%, while AZN is up 13.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, MRNA is down 34.6%, PFE is down 7%, SNY is down 0.7%, while AZN is up 13.1%. (Photo credit: Getty Images)

Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca 

The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting funding toward broader vaccine platforms.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Current Price	$24.83
Prev Close	$25.14
Open	$24.93
Dividend Yield	0.00%
50-Day Moving Average	$28.84
Beta	1.23
Avg. Volume	9.38M
PE Ratio	-3.34

52-Week High	$79.96
52-Week Low	$23.15
Market Capitalization	$9.78B
EPS (Annual)	-$9.27
Price to Book	1.04
Revenue Per Employee	$557,931.03
Enterprise Value/EBITDA	N/A

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNA Moderna Inc